This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignee: Tosk, Incorporated. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Innovations of Stephen D. Yanofsky
Introduction
Stephen D. Yanofsky is a notable inventor based in Mountain View, California. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target RAS GTPase. With a total of three patents to his name, Yanofsky's work is focused on addressing critical health issues, including cancer.
Latest Patents
Yanofsky's latest patents include innovative compounds known as heteroaryl modulators of RAS GTPase. These RAS modulating compounds are designed to modulate the activity of target RAS proteins in biological samples. The target RAS can be a mutant form implicated in various diseases, particularly cancers driven by kRAS or mutated kRAS. His patents detail methods for treating RAS-driven diseases by administering therapeutically effective amounts of these compounds. Additionally, the patents cover pharmaceutical compositions and kits that incorporate these subject compounds, showcasing their potential in clinical applications.
Career Highlights
Stephen D. Yanofsky is currently associated with Tosk, Incorporated, where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to the understanding and treatment of RAS-related diseases.
Collaborations
Yanofsky collaborates with esteemed colleagues, including Solomon B. Ungashe and Annie L. Lennek. These partnerships enhance the innovative potential of his research and contribute to the development of effective therapeutic solutions.
Conclusion
Stephen D. Yanofsky's contributions to the field of biotechnology through his patents and collaborations highlight his commitment to addressing significant health challenges. His work in modulating RAS GTPase represents a promising avenue for cancer treatment and showcases the impact of innovation in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
